Impact of CIGB-258 on the survival of severely ill patients with COVID-19
Keywords:
COVID-19, CIGB-258, survivalAbstract
Introduction: COVID-19 produces an acute respiratory disease with high morbidity and mortality. CIGB-258 controls the inflammatory response, survival and favorable impact on the variables of the predictive model.
Objective: Show the impact of CIGB-258 on the survival of patients with COVID-19
Methods: Retrospective descriptive study, in 69 seriously ill patients with COVID-19, at the “Salvador Allende” Hospital, from March to May 2020, the sample selected by inclusion criteria and by random assignment, grouped into two groups, Group 1: 37 treated patients with standardized protocol and Group 2: 32 patients with standardized protocol and CIGB-258. With the model, the risk of death and survival was stratified from admission to discharge and death of the patients. The variables age, respiratory rate, creatinine, systolic and diastolic blood pressure, oxygen pressure, hemoglobin and sodium, history of high blood pressure, diabetes and obesity were operationalized. Means, medians, Levene's Test, Bartholomew's test, Studenst T, and standard deviation were determined. The principles of biomedical research were complied with.
Results: With the use of CIGB-258, the evolution was satisfactory in 72 hours, the time from admission to discharge was 6-9 days, time between admission and death was 10-12 days, reduction to low risk of death according to model and greater survival in patients
Conclusions: The CIGB-258 peptide reduces the time until patients are discharged and reduces the risk of death. The model shows the impact of treatment on the survival of patients with COVID-19.
References
1. Medeiros-Figueiredo A, Daponte-Codina A, Moreira-Marculino D, Toledo-Vianna R. Factores asociados a la incidencia y la mortalidad por COVID-19 en las comunidades autónomas. Gac Sanit [Internet]. 2020 [citado:28/06/2020]; 35(5): 445-452. Disponible en : https://www.ncbi.nlm.nih.gov/pmc /articles/PMC7260480/
2. Reyes-Bueno J, Mena-Vázquez N, Ojea -Ortega T, González-Sotomayor M, Cabezudo-García P, Ciano-Petersen N, et al. Análisis de letalidad por COVID-19 en pacientes con demencia neurodegenerativa. Neurología [Internet]. 2020 [citado: 02/04/2021]; 35 (9): 639–645. Disponible en: https://www.ncbi.nlm. nih.gov/pmc /articles/PMC7386259/
3. Larici AR, Cicchetti G, Marano R, Merlino B, Elia L, Calandriello L, et al. Multimodality imaging of COVID-19 pneumonia: from diagnosis to follow-up. A comprehensive review. Eur J Radiol [Internet]. 2020 [citado: 04/01/2020]; 131: 109217. Disponible en: https://www.ncbi.nlm.nih.gov /pmc/articles/PMC7430292/
4. Suárez V, Suarez-Quezada M, Oros-Ruiz S, Ronquillo-De Jesús E. Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020.Rev Clin Esp [Internet]. 2020 [citado: 02/04/2021]; 220 (8): 463–471. Disponible en: https://www.revclinesp.es/es-pdf-S0014256520301442
5. Mojica-Crespo M, Morales-Crespo MM. Pandemia COVID-19, la nueva emergencia sanitaria de preocupación internacional: una revisión. Semergen [Internet].2020 [citado: 30/03/2021]]; 46:65-77. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229959/
6. Muk-Choi H, Youn-Moon S, In-Yang H, Soo-Kim K. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. Int J Mol Sic [Internet]. 2021 [citado: 02/03/2021]; 22 (4): 1737. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC7915126/
7. González-Fajardo J, Ansuategui M, Romero C, Comanges A, Gómez-Arbeláez D, Ibarra G, et al. Mortalidad de los pacientes covid-19 con complicaciones trombóticas. Med Clin (Barc) [Internet]. 2021 [citado: 02/04/2021]; 156 (3): 112–117. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/P MC7834534/
8. Zhang S, Yangyang L, Xiaofang W, Li Y, Haishan L, Yuyan W, et al. SARSCoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol [Internet]. 2020; 13 (120): 2-22. DOI: https://doi.org/10.1186/s13045-020-00954-7
9. Sáenz-Morales O, Rubio A, Yomayusa N, Gamba N, Garay-Fernández M. Coagulopatía en la infección por el virus SARS-CoV-2 (COVID-19): de los mecanismos fisiopatológicos al diagnóstico y tratamiento. Acta Colombiana de Cuidado Intensivo [Internet]. 2020 [citado: 02/04/2021]; 22 (1): 44-54. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659516/pdf/main.pdf
10. Bernard I, Limonta D, Mahal L, Hobman T. Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. Viruses [Internet]. 2021 [citado: 04/06/2021]; 13 (1): 29. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823949/
11. Giraldo-Alzate C, Tamayo-Múnera C, López-Barón E, Caicedo-Báez M, Piñeres-Olave B. Síndrome inflamatorio multisistémico en niños asociado a COVID-19. Revisión narrativa de la literatura a propósito de un caso. Acta Colombiana de Cuidado Intensivo [Internet]. 2020 [citado: 30/03/2021]; 22 (2): 137-48. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 7680037/
12. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID 19 associated with acute respiratory distress syndrome. Lancet Respir Med [Internet]. 2020 [citado: 08/04/ 2021]; 8 (4): 420-422. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32085846/
13. Yhojan-Rodrígueza Y, Novellib L, Rojasa M, De Santisb M, Acosta-Ampudia Y, Monsalvea D, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. Journal of Autoimmunity [Internet]. 2020 [citado: 23/06/2020]; 114: 102506.Disponible en: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC7296326/pdf/main.pdf
14. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect [Internet]. 2020 [citado: 23/06/2020]; 80 (6): 639-645. Disponible en: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC7118526/
15. Kang S, Peng W, Zhu Y. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents[Internet]. 2020 [citado: 24/06/2020]; 55 (5): 105950. Disponible en: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC7118423/
16. Du R, Liang L, Yang C, Wang W, Cao T, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J [Internet]. 2020 [citado: 28/06/2020]; 55 (5): 2000524. Disponible en: https://erj.ersjournals.com/content/55/5/2000 524
17. Hernández-Cedeño M, Venegas-Rodríguez R, Peña-Ruiz R, Bequet-Romero M, Santana-Sánchez R, Penton-Arias E, et al. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Cell Stress and Chaperones [Internet]. 2021 [citado: 08/04/2021]; 26 (3): 515-525. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC7904296/
18. Barberá A, Lorenzo N, van Kooten P, van Roon J, de Jager W, Prada D, et al. APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4 + T cells from rheumatoid arthritis patients. Cell Stress ad Chaperones [Internet]. 2016 [citado: 28/10/2023]; 21 (4): 735–744. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908004/pdf/12192_2016_Article_698.pdf
19. Venegas-Rodríguez R, Peña-Ruiz R, Santana-Sánchez R, Bequet-Romero M, Hernández-Cedeño M, Santisteban-Licea B, et al. Péptido inmumodulador CIGB-258 para el tratamiento de pacientes graves y críticos con la COVID-19. Revista Cubana de Medicina Militar [Internet]. 2020 [citado: 28/10/2023];4 9 (4): e0200926. Disponible en: https://revmedmilitar.sld.cu/index.php/mil/article /view/926
20. García-Álvarez PJ. Validación externa del modelo predictivo de mortalidad en ancianos con neumonía adquirida en la comunidad. Rev Med Electrón [Internet]. 2020 [citado: 07/11/ 2023]; 42(6): 2560-2574. Disponible en: http://scielo.sld.cu/ scielo.ph?script=sci_ arttext&pid =S1684-18242020000 602560&lng=es
21. Plasencia-Urizarri TM, Aguilera-Rodríguez R, Almaguer-Mederos LE. Comorbilidades y gravedad clínica de la COVID-19: revisión sistemática y meta-análisis. Rev haban cienc méd [Internet]. 2020 [citado: 01/07/2024]; 19 (supl.): e3389. Disponible en: http://www.revhabanera.sld.cu/ index.php /rhab/article/view/3389
22. Díaz-Narváez VP. Regresión Logística y Decisiones Clínicas. Nutr Hosp [Internet]. 2017 [citado: 05/11/23]; 34 (6): 1505. Disponible en: https://scielo.isciii.es/pdf/nh/v34n6/36_diaz.pdf
23. Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020 [citado:08/04/2021]; 395 (10229): 1033-1034. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32192578/
24. Domínguez MC, Cabrales A, Lorenzo N, Padrón G, González LJ. Biodistribution and pharmacokinetic profiles of an Altered Peptide Ligand derived from Heat-shock proteins 60 in Lewis rats. Cell Stress and Chaperones [Internet]. 2020 [citado: 20/11/2020]; 25 (1): 133-140. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31802366/
25. Padilla M. Vacunas cubanas contra la COVID-19. Sus impactos sociales en Cuba y en el mundo. Cuadernos de nuestra América. Nueva época [Internet]. 2022 [citado: 20/11/2020]; (5): 152-170. Disponible en: http://www.cna.cipi. cu/cna/article /view/113/372
26. Benítez-Martínez M, Revueltas-Agüero M. Aspectos relacionados con las vacunas contra la COVID-19 en el mundo y en Cuba. Noviembre 2022. Rev haban cienc méd [Internet]. 2022 [citado:01/07/2024]; 21(5): e5079. Disponible en: http://scielo.sld.cu/pdf/rhcm/v21n5/1729-519X-rhcm-21-05-e5079.pdf
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pedro Julio García Álvarez, Alberto García Gómez, Eglis Fernández Castillo, Jaqueline Nistal Mena, Liuba Luisa Arteche Hidalgo, Osyari Ipsan Muñoz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
